Banner image

Investor Relations

A diversified portfolio

Ackermans & van Haaren concentrates on a limited number of strategic participations with an important potential for growth.

AvH is listed on Euronext Brussels and is included in the BEL20 index, the BEL ESG index and the European DJ Stoxx 600 index.

Shareholder information

Ackermans & van Haaren attaches great importance to transparent information and direct dialogue with shareholders.
Tabbed feature dummy image

Results centre

The Results centre provides access to annual reports, mid-year reports, investor presentations and related videos.

Tabbed feature dummy image

Financial calendar

Mark the publication dates of full-year results, mid-year results and interim statements.

Tabbed feature dummy image

General meetings

All information and documents for the general shareholder meetings can be found here.

Tabbed feature dummy image

Share price

The shares of Ackermans & van Haaren are listed on Euronext Brussels. Follow the share price evolution.

Tabbed feature dummy image

Investment calculator

A handy tool for tracking and comparing the value of your investment in Ackermans & van Haaren.

Tabbed feature dummy image

Shareholder structure

How is the shareholdership of Ackermans & van Haaren structured? Discover it here
Tabbed feature dummy image

Analysts

The Ackermans & van Haaren share is covered by a sell-side analyst from 8 renowned brokers. In an overview, we mention their names, the publication date of their most recent report, their recommendation and target price.

Key financial highlights

At an economic level, the AvH group represented in 2025 a pro forma turnover of 7.7 billion euros and employed 24,931 people through its share in the participations. The group concentrates on a limited number of strategic participations with an important potential for growth.

Net result (2025)

593 m

Shareholders’ equity (31 Dec. 2025)

5,701 m

Net cash (31 Dec. 2025)

429 m

Recent press releases

View all
Growth Capital
April 30, 2026

Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554

Growth Capital
April 29, 2026

Biotalys Reports Full-Year 2025 Financial Results and Business Highlights

Growth Capital
April 27, 2026

Biotalys Achieves First U.S. State Registration for EVOCA in Florida

Investor contact

We foster an open dialogue with our shareholders and investors.